Although the adverse effects of cannabis use have a complex pattern, most reviews report that it was associated with fewer adverse events compared to a placebo. Of the 59 reviews, forty-nine dealt with pain; the remaining thirty-nine focused on non-pain conditions. Of these studies, 21 reported significant adverse effects of cannabis use; the remaining reviews did not distinguish between serious and minor adverse events. Minor adverse effects included nausea, dizziness, and somnolence.
The outcomes reported in the reviews varied by type of cannabis and study population. In the case of cancer, two reviews evaluated cannabis as a treatment for nausea following chemotherapy. Other reviews assessed the effectiveness of cannabis in general, and seven reported on specific conditions. However, it is unclear whether placebo was used in all of these studies. Many reviewed the safety and efficacy of cannabis for a variety of conditions, including anxiety and pain. Cannabis has many potential benefits, and it is a safe option for many patients with chronic medical conditions.
The National Academy of Sciences recently released a study of 66 studies that found no association between chronic cannabis use and a risk of acute myocardial infarction. In fact, some studies have argued that cannabis and ill consequences have similar origins. However, further research is needed to determine whether cannabis use actually contributes to the development of ill consequence. If so, which factors should be considered in clinical trials? The following are some recommendations for researchers.
Growing cannabis for therapeutic purposes should be done organically and without the removal of males. In addition to obtaining the maximum amount of cannabinoids, it should be cultivated using tinctures and oils. In the US, we are decades behind the world when it comes to research and development. We should not lag behind our compassionate suppliers when it comes to developing products for medicinal and recreational use. In fact, it is our governments and big pharma that are years behind us.
Studies have shown that patients with inflammatory bowel disease have reduced the frequency and severity of their symptoms after using cannabis. Although no studies have proven that cannabis can reduce the incidence of the disease in humans, preclinical and animal studies suggest that cannabis-derived medicines could limit inflammation and improve glycemic control in people with inflammatory bowel diseases. The findings suggest that cannabis-derived medicines may also help improve the quality of life of chronic hepatitis C patients.
There are many side effects associated with medical cannabis use, which is why a doctor should be your primary care provider when prescribing it. It can interact with other medicines and cause liver malfunction. You would need to see a specialist regularly to monitor any side effects. Cannabis-based medicine is not available at your local GP’s office. It must be prescribed by a medical doctor at a hospital or clinic, who will first discuss alternative therapies.
The FDA continues to be concerned with the proliferation of CBD products without FDA approval. Because the FDA has not yet approved many products made from cannabis for medical or therapeutic purposes, many of these products are sold online. This puts patients at risk. In addition, unapproved products have not been proven to be effective or safe. This deceptive marketing of CBD poses serious public health concerns. It could mislead patients to use these products instead of approved therapies. So, the FDA wants to ensure that cannabis-derived products do not pose a risk to their health.
